



Correction to “New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe” [The Lancet Regional Health – Europe, volume 50, March 2025, 101170]

Lorenza Rimassa,^{a,b,*} Angela Lamarca,^c Grainne M. O’Kane,^{d,e} Julien Edeline,^f Mairéad G. McNamara,^g Arndt Vogel,^{h,i,j} Matteo Fassan,^{k,l} Alejandro Forner,^{m,n} Timothy Kendall,^{o,p,q} Jorge Adeva,^f Andrea Casadei-Gardini,^s Lorenzo Fornaro,^t Antoine Hollebecque,^u Maeve A. Lowery,^v Teresa Macarulla,^w David Malka,^x Elene Mariamidze,^y Monica Niger,^z Anu Ustav,^{aa} John Bridgewater,^{ab} Rocio I. R. Macias,^{n,ac,af} and Chiara Braconi^{n,ad,ae,af,**}

^aDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, 20072, Italy

^bMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via A. Manzoni 56, Rozzano, Milan, 20089, Italy

^cDepartment of Medical Oncology, Oncohealth Institute, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Fundación Jiménez Díaz University Hospital, Avda Reyes Católicos 2, Madrid, 28040, Spain

^dUniversity College Dublin, Belfield, Dublin 4, Ireland

^eDepartment of Medical Oncology, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland

^fINSERM, Department of Medical Oncology, University Rennes, CLCC Eugène Marquis, COSS [(Chemistry Oncogenesis Stress Signaling)] – UMR_S 1242, Rennes, F-35000, France

^gDivision of Cancer Sciences, University of Manchester & Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK

^hToronto General Hospital, UHN, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada

ⁱPrincess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada

^jHannover Medical School, Carl-Neuberg Str. 1, Hannover, 30659, Germany

^kDepartment of Medicine (DIMED), University of Padua, Via Gabelli 61, Padua, 35121, Italy

^lVeneto Institute of Oncology (IOV-IRCCS), Via Gattamelata 64, Padua, 35128, Italy

^mLiver Unit, Barcelona Clinic Liver Cancer (BCLC) Group, ICMDM, Hospital Clinic IDIBAPS, University of Barcelona, Villarroel 170, Barcelona, 08036, Spain

ⁿCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Av. Monforte de Lemos, 3-5, Madrid, 28029, Spain

^oCentre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU, UK

^pEdinburgh Pathology, University of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK

^qCRUK Scotland Cancer Centre, Switchback Rd, Glasgow, G61 1BD, UK

^rDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Av. de Córdoba, s/n, Usera, Madrid, 28041, Spain

^sDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Via Olgettina 60, Milan, 20132, Italy

^tMedical Oncology 2 Unit, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, Pisa, 56126, Italy

^uDépartement de Médecine Oncologique, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, F-94805, France

^vTrinity St James Cancer Institute, Trinity College Dublin, College Green, Dublin 2, Ireland

^wVall d’Hebrón Institute of Oncology (VHIO), Vall d’Hebrón University Hospital, Centre Cellex, Carrer de Natzaret, 115-117, Barcelona, 08035, Spain

^xDepartment of Medical Oncology, Institut Mutualiste Montsouris, 42 Boulevard Jourdan, Paris, 75014, France

^yDepartment of Oncology and Hematology, Todua Clinic, Tevdore Mgvdeli #13, Tbilisi, 0112, Georgia

^zMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, Milan, 20133, Italy

^{aa}Clinic of Oncology, North-Estonian Medical Centre, Sytiste Rd 19, Tallinn, 13419, Estonia

^{ab}UCL Cancer Institute, 72 Huntley St, London, WC1E 6DD, UK

DOI of original article: <https://doi.org/10.1016/j.lanepe.2024.101170>

*Corresponding author. Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, Pieve Emanuele, Milan, 20072, Italy.

**Corresponding author. School of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Switchback Rd, Glasgow, G61 1BD, UK.

E-mail addresses: lorenza.rimassa@hunimed.eu (L. Rimassa), chiara.braconi@glasgow.ac.uk (C. Braconi).

© 2025 The Author(s). Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

^{af}Contributed equally as last authors to this work.

^{ac}Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, University of Salamanca, IBSAL, CIBERehd, Campus M. Unamuno s/n, Salamanca, 37007, Spain

^{ad}School of Cancer Sciences, University of Glasgow, Switchback Rd, Glasgow, G61 1QH, UK

^{ae}Beatson West of Scotland Cancer Centre, 1053 Great Western Rd, Glasgow, G12 0YN, UK

The Lancet Regional
Health - Europe
2025;53: 101306

Published Online 30 April
2025

<https://doi.org/10.1016/j.lanep.2025.101306>

The authors regret the mistake in Table 2: Targeted therapies for advanced biliary tract cancers: Median overall survival in the HERIZON-BTC-01 phase 2 trial of zanidatamab was 15.5 months in the HER2+ population, while the table shows 5.5 months. In the Lancet Oncology publication cited in the manuscript OS was not mature, and the OS of 15.5 months was reported at ASCO 2024.¹

The authors would like to apologise for any inconvenience caused.

Reference

- 1 Pant S, Fan J, Oh D-Y, et al. Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study. *J Clin Oncol.* 2024;42(suppl 16):abstr 4091.